Mounjaro reacții adverse: what the evidence says about tirzepatide's side effects

What the SURMOUNT trials recorded, and what 'common' actually means here

The SURMOUNT-1 trial, published in the New England Journal of Medicine and forming the backbone of NICE's appraisal of tirzepatide (TA1026), enrolled 2,539 adults with obesity over 72 weeks. Adverse effects were recorded systematically, which is worth knowing because it means the rates you read about come from controlled observation, not anecdote. Nausea was the most commonly reported event, followed by diarrhoea, vomiting and constipation. Across all active dose groups, the large majority of these events were graded mild or moderate. Fewer than 5% of participants discontinued treatment specifically because of gastrointestinal reactions at the maintenance doses.

There is a widespread assumption that these medicines cause unrelenting sickness. That is not what the trial data show. Reactions tend to cluster around two predictable moments: the first few weeks on any new dose, and the transition to a higher one. Between dose steps, GI symptoms typically ease. Eating smaller portions, avoiding fatty or very rich food, and staying well hydrated all appear to reduce the intensity of early nausea, and these are practical steps, not just reassurances. If symptoms remain severe or do not settle, that is a conversation for your prescriber, not something to push through silently.

Other effects recorded in trials include injection-site reactions (redness, mild swelling, itching at the abdomen, thigh or upper arm), fatigue, headache and dizziness, particularly early on. A fuller breakdown of tirzepatide's side-effect profile covers the less common reactions in more detail.

The side effects that require urgent medical attention

Most reactions on Mounjaro are manageable and self-limiting. A smaller number are signals that need prompt medical assessment. The MHRA's Drug Safety Update of 29 January 2026 identified acute pancreatitis as a known but infrequent adverse effect of GLP-1 receptor agonist medicines including tirzepatide. The alert describes it as potentially serious. The symptom to act on is severe, persistent stomach pain (particularly pain that spreads toward the back) with or without vomiting. That combination warrants same-day medical review, not watchful waiting.

Gallbladder problems, including gallstones and cholecystitis, have also been reported in trials at rates higher than background. Right-sided or upper abdominal pain, especially after eating, is worth raising with a clinician. Dehydration from prolonged vomiting or diarrhoea can put strain on the kidneys; if you cannot keep fluids down for more than 24 hours, seek help. Signs of a serious allergic reaction (widespread rash, difficulty breathing, swelling of the face or throat) need emergency attention. People with type 2 diabetes who are also on insulin or a sulphonylurea should be aware of the increased hypoglycaemia risk; this is managed at prescribing stage but worth knowing.

You can report any suspected reaction using the Yellow Card scheme, this data actively shapes how the MHRA monitors tirzepatide under its Black Triangle status. Our prescriber advice page explains how to raise a concern with the clinical team between appointments.

Contraception, HRT and other interactions worth knowing before you start

The interaction between tirzepatide and oral contraceptives is one that catches people off guard, and it is worth addressing plainly. Because Mounjaro slows gastric emptying, it can reduce the absorption of oral medicines taken at the same time, including the combined or progestogen-only pill. NHS guidance is clear: during the first four weeks of tirzepatide treatment, and for four weeks after each dose increase, a non-oral method of contraception (condoms, for example) should be used alongside the pill. After those windows, oral contraception can be relied upon as normal. This is not a reason to avoid treatment; it is a reason to plan.

For women using oral HRT, NHS England advises considering transdermal formulations (patches or gels) while on tirzepatide, for the same absorption reason. This is a discussion for your GP or prescriber before you begin. If you are pregnant, breastfeeding or actively trying to conceive, Mounjaro is not recommended; the prescriber will discuss appropriate timing and contraception planning as part of your consultation. People under 18 are outside the licensed indication. How tirzepatide works at the receptor level provides more context on why GI effects and absorption changes occur. If you are considering the cost implications of long-term treatment, the Mounjaro cost page sets out what private prescriptions typically include in the UK.

Living with side effects on treatment, and when they ease

One thing our prescribers hear regularly is that people expect to feel worse for longer than they actually do. For many, the nausea that arrives with the first pen has largely resolved by week three or four. The pattern tends to repeat with each dose step, though usually with diminishing intensity as the body adapts. This is not guaranteed, and individual responses vary, but the trajectory the trials documented is an improvement over time, not a plateau of discomfort.

Practical steps that help: eating a small, low-fat meal rather than skipping food entirely, sitting upright for a while after eating, and drinking water steadily through the day rather than in large amounts at once. Alcohol can worsen nausea and is worth reducing, particularly in the early weeks. Detailed guidance on adjusting daily habits while on treatment is covered on the tirzepatide overview page. For people approaching their target weight and wondering what comes next, what happens when you reach your goal weight on Mounjaro addresses how treatment is reviewed at that stage. Our clinical team reviews every patient's progress before repeat prescriptions are issued, side effects are part of that review, not an afterthought. If you have questions between orders, our support team is available seven days a week.

Mounjaro is a prescription-only medicine. If you are thinking about whether it could be suitable for you, the right starting point is a clinical assessment. Check your eligibility with our prescribers, consultations are free, and the same prescriber who reviews your answers will make the clinical decision.